X enotransplantation holds the potential to provide an unlimited source of donor organs for human transplantation (1-3). However, its application is dependent upon overcoming the major stages of rejection: hyperacute rejection and delayed xenograft rejection (DXR). 3 The mechanisms of hyperacute rejection have been studied extensively, and attempts to reduce its occurrence have been successful (4 -6) . Conversely, DXR, which is characterized by thrombosis and, to a lesser extent, the infiltration of monocytes and NK cells into the xenograft, is poorly understood. The development of DXR is currently believed to involve four major interrelated pathways: the coagulation system, endothelial activation, platelet aggregation, and monocyte and NK cell infiltration (7) (8) (9) (10) (11) (12) .
Monocyte infiltration to the xenograft occurs as early as 4 -6 h after transplantation and persists until the complete rejection of the graft (13) . The mechanism of monocyte accumulation within the xenograft is not completely understood. However, the existence of a lectin-dependent recognition pathway could be one of the mechanisms by which host monocytes specifically recognize xenografts, a theory that is supported by several studies (8) . For example, studies in a guinea pig-to-rat xenograft model have demonstrated that host monocyte infiltration persists in the absence of complement or a chemokine-dependent mechanism, and that 80% of the accumulated monocytes were positively detected by a galactose/ N-acetylgalactosamine-specific mAb (14) . Our previous study has also demonstrated that human monocytes have the capacity to bind to the major xenoantigen ␣-gal (15) . The evidence underpinning the existence of a lectin-dependent xeno-Ag recognition pathway is considerable; however, the exact receptor that mediates this binding has not yet been identified.
Galectin-3 is a ϳ30-kDa lectin composed of a C-terminal carbohydrate recognition domain, which is responsible for the specific recognition of ␤-galactosides (Gal␤(1-3/4)GlcNAc), and an Nterminal domain. Galectin-3 is diversely expressed in mammalian cells, including monocytes and macrophages, and it has an extremely high affinity for the Galili pentasaccharide, of which the last three sugars constitute the major xenoantigen, Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R (16 -19) . In this study, we have used flow cytometry, Western immunoblotting, affinity pull-down assays, and blocking Ab studies to demonstrate that the interaction of ␣-gal and human monocytes is mediated by Galectin-3.
Materials and Methods

Abs and reagents
Mouse anti-human Galectin-3 (clone B2C10) was purchased from BD Biosciences. Purified recombinant human Galectin-3 was obtained from PeproTech. Immobilized streptavidin-agarose beads and ECL kit were purchased from Pierce. Monocyte separation kits were purchased from Miltenyi Biotec. The secondary Ab used for flow cytometry, PE-conjugated F(abЈ) 2 of affinity-purified anti-mouse IgG (F(abЈ) 2 goat Ig), was from Rockland. The secondary Ab used for Western immunoblotting (goat anti-mouse HRP) was from Bio-Rad. Endothelial mitogen was purchased from Biomedical Technologies.
Soluble polymeric Gal-a(1,3)Gal-␤(1,4)GlcNAc-R derivatives conjugated to poly(N-(2-hydroxyethyl)acrylamide) (PAA) were purchased from Lectinity: HOCH 2 (HOCH) 4 CH 2 NH-(control-PAA,0000), HOCH 2  (HOCH) 4 CH 2 NH-PAA-FITC (control-PAA-FITC, 0000-FP), and Gal␣1-3Gal␤1-4GlcNAc␤-OCH 2 CH 2 CH 2 NH-PAA-FITC (␣-Gal-PAA-FITC,  0070-FP) . The GAS914 reagent (Gal␣1-3Gal␤1-4GlcNAc␤-poly(lysine)) was a gift from G. Levy (University of Toronto, Toronto, Canada) and biotinylated in our lab using standard techniques.
PBMC and monocyte isolation
Whole human blood from healthy donors was collected into syringes containing heparin and carefully layered onto Ficoll-Paque 1077 (SigmaAldrich). PBMCs were obtained from the interface between human plasma and the Ficoll-Paque following density gradient centrifugation at 400 ϫ g. Monocytes were then isolated from platelet-depleted PBMCs by negative selection based on the depletion of neutrophils, dendritic cells, basophils, granulocytes, and B, T, and NK cells with a mixture of biotinylated mAbs, followed by a secondary anti-biotin Ab conjugated to magnetic beads. Flow cytometry routinely demonstrated that greater than 85% of the cells in the monocyte fraction were CD14
ϩ .
Endothelial cells
Cultured human aortic endothelial cells (HAEC) were obtained from Cambrex. Detailed methods for isolating porcine aortic endothelial cells (PAEC) were described in our previous study (15) . In brief, freshly harvested porcine aortas (from a local slaughterhouse) were treated with 0.1% collagenase (Sigma-Aldrich) at 37°C to liberate endothelial cells. These cells were then collected and washed with DMEM (Invitrogen Life Technologies) ϩ 10% FBS to inactivate the collagenase and resuspended in DMEM ϩ 10% FBS (with Pen/Strep and 25 g/ml endothelial mitogen) and plated in a Corning T25 tissue culture flask. PAEC and HAEC were grown to confluence and used for experiments between the second and sixth passage. For adhesion assays, both HAEC and PAEC were cultured to confluence on a gelatin (2%)-coated 96-well tissue culture plate (Falcon).
Static adhesion assay
HAEC and PAEC were seeded onto a 96-well plate and incubated for 2 days until confluent. On the day of the experiment, human monocytes were isolated and resuspended in HBSS at 2 ϫ 10 6 cells/ml. Cells were labeled with Calcein-AM at 4 M at 37°C for 30 min. After being washed twice in HBSS buffer, 5 ϫ 10 4 labeled monocytes were applied to each of the preseeded wells of HAEC or PAEC in triplicate. Fluorescence was measured with a Cytofluor 4000 II multiwell plate reader (Applied Biosystems) using 485 nm excitation and 530 nm emission filters. Readings were performed on plates before cell loading (background), immediately after the incubation with cells (full) and after 30 min of adhesion and washing three times. Assays were performed in triplicate and repeated on at least three different days, using different monocyte donors. Results are displayed as mean adhesion as percentage of full signal, calculated as follows (20) : percentage of adhesion ϭ (value (well) -background (well) )/(value (full) Ϫ background (well) ) ϫ 100.
Parallel plate flow chamber assay
Adhesion assays were performed using a parallel plate flow chamber (Glycotech) at a shear stress of 0.8 dyne/cm 2 . Confluent monolayers of PAEC were mounted in the flow chamber and placed on the stage of a Nikon Diaphot 300 inverted phase-contrast microscope. Experiments were videotaped with a Sony DXC-151A color video camera and Sony SVT-S3100 time-lapse video cassette recorder for later offline analysis. Purified monocytes (0.5 ϫ 10 6 ) were resuspended in 500 l of HBSS (with 1 mM Ca 2ϩ / Mg 2ϩ ) supplemented with 10 mM HEPES and 0.5% FBS (assay buffer) and injected into the flow chamber. Adherent monocytes were counted in six consecutive high-power fields after 4 min of flow. Monocytes were considered firmly adherent if they remained stationary for Ͼ4 s. It was unusual for adherent monocytes to subsequently release.
Flow cytometric analysis
The capacity of human monocytes to bind to ␣-gal was determined by incubating PBMCs obtained from healthy donors with soluble ␣-gal-FITC (0070-PAA-FP) or control glycoconjugate-FITC (0000-PAA-FP) for 30 min at 4°C. Before incubation with glycoconjugates, nonspecific binding sites were blocked by incubating with 500 mg/ml 0000-PAA for 20 min at 4°C. The correct flow cytometer gating for monocytes was previously established using Abs specific for CD14. The mean fluorescence intensity (MFI) of each gated population was then determined by flow cytometry.
The surface staining of PBMCs with Galectin-3 was performed by incubating the cells with 25 g/ml mouse anti-human Galectin-3 Ab on ice for 30 min, followed by the incubation of PE-conjugated goat anti-mouse Ab on ice for 30 min. For intracellular staining, the PBMCs were fixed with 4% paraformaldehyde and permeabilized with 0.05% saponin in PBS before the primary Ab incubation. MFI was then measured for both monocytes and lymphocytes.
Binding of Galectin-3 to endothelial cells was performed by incubating the cells with 50 g/ml purified recombinant human Galectin-3 and either 50 mM sucrose or lactose for 20 min at 4°C. Cells were subsequently stained for surface Galectin-3 as above. The glycosylation of PAEC was modified by treating a confluent monolayer with 2 U/ml of an ␣-exogalactosidase (Sigma-Aldrich) intact or heat inactivated (100°C for 20 min), or ␤-exogalactosidase (Sigma-Aldrich) in HBSS for 2 h at 37°C. Verification of digestion of Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R was shown by flow cytometry staining using 10 g/ml FITC-labeled Bandeiraea simplicifolia isolectin B 4 ((BS-IB 4 )-FITC) before and after exogalactosidase treatment.
Binding capacity of Galectin-3 to ␣-gal
Pure protein samples of BSA, BSA-IB4, or Galectin-3 were added to a Nunc Maxi-sorp plate (Nalge Nunc International) at 100 g/ml at 4°C overnight. On the following day, the plate was washed with PBS three times and blocked with 1% of BSA at room temperature for 1 h. Glycoconjugates (0070-FP or 0000-FP) were then applied to the precoated wells at room temperature for 30 min. The plate was then washed three times with PBS, and the fluorescent signal from each well was measured using a CytoFluor plate reader.
Western blotting
Human monocytes and lymphocytes were isolated, as described above. The cells were washed twice with PBS and then lysed using lysis buffer (PBS plus 1% Nonidet P-40 with 1 mM PMSF, and 10 g/ml aprotinin, leupeptin, and pepstatin A). The cell lysates were then separated by electrophoresis on a 10% SDS-PAGE gel at 100 V for 2 h, transferred to nitrocellulose membrane using an electric transfer cell at 18 V for 45 min, and blocked with 5% nonfat milk in PBS. The blot was then probed with mouse antihuman Galectin-3 mAb, followed by detection using goat anti-mouse HRP and an ECL kit to expose photographic film (Pierce Biotechnology).
Affinity precipitation assay
Cell lysates from human monocytes or lymphocytes were incubated with or without GAS914-biotin at 4°C overnight. On the following day, streptavidin beads were applied to each sample and incubated for another 4 h at 4°C. Beads were washed three times in PBS with 1% Nonidet P-40, and bound protein was eluted with SDS-PAGE sample buffer (100 mM Tris (pH 6.8), 2% SDS, 0.01% bromphenol blue, and 10% glycerol). The samples were then separated by SDS-PAGE, and Galectin-3 expression was detected with anti-human Galectin-3 Ab described as above.
Statistical analysis
Statistical analysis was performed with SPSS software (SAS version 8.1; SAS Institute). Comparisons of variables between groups were performed with unpaired Student's t tests or ANOVA. A two-tailed p value Ͻ0.05 was considered statistically significant.
Results
Human monocytes adhere to porcine, but not human endothelium
Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R is expressed on many different cell types, including endothelial cells from nonhuman species. To confirm this pattern of expression, we first examined the level of expression on HAEC and PAEC using the BS-IB 4 . As expected, HAEC exhibited no detectable BS-IB 4 -FITC fluorescence, whereas a tremendously high level of Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R was detected on the surface of PAEC (Fig. 1A , Ϫ31 Ϯ 23 vs 3685 Ϯ 178 arbitrary fluorescence units; p Ͻ 0.0001). We then examined the interaction between human monocytes and endothelial cells under static adhesion conditions. Specifically, after coculturing human monocytes with either HAEC or PAEC at 37°C for 30 min, a much higher proportion of human monocytes bound to PAEC as opposed to HAEC (23.51 Ϯ 1.94 vs 4.03 Ϯ 1.63% adhesion; p ϭ 0.0001; Fig. 1B) . Moreover, previous studies from our group have documented that the high expression level of Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R on porcine endothelial cells contributes to the elevated levels of firm adhesion to xenogeneic endothelial cells by human monocytes (15) .
␣-Gal is a ligand for human monocyte lectins
We hypothesized that Gal-a(1,3)Gal-␤(1,4)GlcNAc-R could bind directly to human monocytes through a lectin-type recognition pathway. Indeed, we have previously demonstrated specific and saturable binding of a soluble Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R fluorescent probe to monocytes in suspension (15) . Interestingly, monocytes obtained from different donors showed a variation in MFI, while there was essentially no binding to lymphocytes ( Fig.  2A) . Confocal microscopy of the cells indicates significant uptake of this fluorescent probe (Fig. 2Bii) , with most of the signal located intracellularly, providing cells are allowed to warm up after binding the probe. Control glycoconjugate was not evident either on the cell surface or intracellularly, using the same exposure time and gain to obtain the microscopic images (Fig. 2Biv) . Interestingly, this variable binding was reproducible when the same donors were examined repeatedly over a span of months to years. Among the donors that were tested, the lowest, median, and highest are presented in Fig. 3A . As previously reported, there is minimal staining of the lymphocyte population, perhaps representing NK cells. The monocytes show a second population shifted to the right compared with the unstained sample, and the size and MFI of this high ␣-galbinding population varied among different donors. This variability between donors was quite reproducible when donors were re-examined. Fig. 3B represents all nine donors that have undergone repeat examination. Note the small SD within a donor compared with the large variability between donors. 
Galectin-3 is expressed in human monocytes and can bind ␣-gal
Cell lysates from human monocytes and lymphocytes were subjected to SDS-PAGE and immunoblotted for Galectin-3. As shown in Fig. 4A , a band ϳ30 kDa was detected in human monocyte cell lysates, but not lymphocytes. Furthermore, we examined where Galectin 3 is expressed in the monocyte by complementary surface (Fig. 4 , B and C) and intracellular (Fig. 4, D and E) staining, followed by flow cytometry. The intracellular staining was very consistent with the Western blot data with high expression of Galectin-3 in monocytes, but not lymphocytes. As expected, lymphocyte surface Galectin-3 expression was essentially undetectable. Monocyte surface expression was also very low, but definitely above isotype control Ab staining.
Because Galectin-3 has been previously found to have a Ca 2ϩ -independent affinity for the Galilli Ag and has been found to be expressed on macrophages, we theorized that it could potentially be a receptor of Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R in human monocytes. To test this hypothesis, we first examined the ability of Galectin-3 to bind Gal-a(1,3)Gal-␤(1,4)GlcNAc-R and the requirement for Ca 2ϩ . BSA, Galectin-3, or BS-IB 4 (as a positive control) was coated to a plate, which was then washed and incubated with ␣-Gal-PAA-FITC or PAA-FITC in the presence or absence of Ca 2ϩ and Mg 2ϩ . As shown in Fig. 5 , Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R bound to both BS-IB 4 and Galectin-3 (71 Ϯ 10 and 36 Ϯ 2 arbitrary fluorescence units), but not BSA (2 Ϯ 2). The absence of Ca 2ϩ had no effect on the interaction of Galectin-3 and Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R (46 Ϯ 3).
␣-Gal directly interacts with Galectin-3
Based on the capacity of Galectin-3 to bind to Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R and its expression in and on human monocytes, we hypothesized that Galectin-3 is the human monocyte receptor for Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R. To prove that monocyte Galectin-3 still possesses the ability to bind Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R (as opposed to the commercial recombinant Galectin-3 used above), we performed affinity purification. Cell lysates from monocytes and lymphocytes were incubated with or without ␣-Gal-containing GAS914-biotin overnight. The next day, the proteins that could interact with the ␣-gal reagent were pulled down using streptavidin beads. The bound protein was eluted and subsequently detected using anti-Galectin-3 Ab in a Western immunoblot. As shown in Fig. 6 , a strong positive band (lane 3) was present in the monocyte cell lysates that were preincubated with GAS914-biotin reagents, whereas those that were not incubated with the GAS914-biotin reagent didn't manifest such a band. This effectively rules out the possibility of nonspecific binding between FIGURE 5. Galectin-3 binds to ␣-Gal in a Ca 2ϩ -independent manner. Control glycoconjugate (Ⅺ) or ␣-Gal-PAA-FITC (f) was applied to BS-IB 4 -or Galectin-3-precoated 96-well plate. ␣-Gal-PAA-FITC bound to both BS-IB 4 and Galectin-3 (71 Ϯ 10 and 36 Ϯ 2 arbitrary fluorescence units), but not to BSA (2 Ϯ 2). The absence of Ca 2ϩ had no effect on the interaction of Galectin-3 and ␣-Gal (46 Ϯ 3). ‫,ء‬ Indicates p Ͻ 0.01; n ϭ 4. FIGURE 6. ␣-gal directly interacts with Galectin-3. Cell lysate from human lymphocytes or monocytes was incubated with or without GAS914-biotin (lane 1 vs 2 for lymphocytes; lane 3 vs 4 for monocytes) plus streptavidin-agarose beads. After washing, bound proteins were eluted with SDS-PAGE sample buffer. Samples were analyzed using Western blot, as described above, using anti-Galectin-3 Ab. Pure Galectin-3 (2 ng in lane 5) was loaded as a positive control. the proteins and the streptavidin beads. Additionally, lymphocyte cell lysates did not show any positive band. Thus, we conclude that human monocyte Galectin-3 can specifically bind ␣-gal.
Galectin-3 binds preferentially to porcine endothelium
To further prove that galectin-3 is the monocyte receptor for Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R, we showed that soluble Galectin-3 binds very highly to PAEC, while almost no binding is seen in HAEC (MFI, 21.07 Ϯ 2.46 vs 1.9 Ϯ 0.61; Fig. 7A ; p Ͻ 0.001) when compared with the baseline levels. To confirm that this binding was a phenomenon of the lectin activity of Galectin-3, endothelial cells were incubated with Galectin-3 in the presence of sucrose, a control disaccharide, or lactose, which has a strong affinity for Galectin-3. The binding of Galectin-3 is almost completely diminished in the presence of lactose (MFI, 0.8 Ϯ 0.17; p Ͻ 0.001).
To determine whether this lectin interaction is due to endothelial Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R, PAEC were treated with exogalactosidases that specifically cleave terminal ␣-galactose sugars. As the amount of Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R is reduced (shown by percentage of baseline MFI), the binding capacity of Galectin-3 decreases (100 to 43.0 Ϯ 6.78% for baseline vs ␣-galactosidase; Fig. 7B ; p Ͻ 0.001).
Blocking Galectin-3 inhibits monocyte adhesion
If Galectin-3 is involved in the increased adherence of human monocytes to PAEC, we hypothesized that the monocytes would show decreased adherence to PAEC if their surface Galectin-3 was blocked. Indeed, upon treatment of human monocytes with antiGalectin-3 Ab vs an isotype control before perfusion over PAEC in a parallel plate flow chamber assay, adhesion was inhibited by ϳ39% (68.48 Ϯ 5.16 vs 41.82 Ϯ 2.58; Fig. 8 ; ‫,ء‬ p ϭ 0.001).
Discussion
Our current investigations provide new insight into a biological function of human Galectin-3 as a receptor for the major xenoantigen Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R. Galectin-3 is expressed by human monocytes and binds Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R. Our previous study demonstrated that adhesion to PAEC was much greater than to HAEC in a laminar flow model. This effect was dependent upon Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R, and Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R was found to induce high-affinity ligand binding of monocyte ␤ 2 integrins (15). Galectin-3 plays diverse roles in inflammation, including the recruitment of leukocytes and the promotion of adhesion (21) (22) (23) (24) . These characteristics prompted us to investigate the role of Galectin-3 in the context of xenotransplantation. Our current observations are that Galectin-3 is expressed in and on monocytes, but not lymphocytes, can bind Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R, and, more importantly, binds extensively to PAEC, much more than to human cells. These findings provide additional support for the concept of a lectinrecognition mechanism that is involved in the attraction and accumulation of monocytes in a xenograft during the course of DXR.
A key difference exists between our current study and the previous one. In the previous study, we found that the fluorescent signal after incubation of polymeric ␣-gal and human monocytes was significantly decreased in the absence of Ca 2ϩ /Mg 2ϩ . This led us to the assumption of the involvement of C-type lectins (15) . Conversely, we demonstrated in the current study that the binding of Galectin-3 to its ligand is calcium independent. We postulate that calcium is, in fact, required for internalization of polymeric ␣-Gal, as shown in Fig. 2B , or potentially in regulating Galectin-3 distribution within the cell, i.e., its delivery to the cell surface.
Although Galectin-3 has no signal sequence, many different types of cell in culture have been found to secrete it (25) (26) (27) . The mechanism behind this apparent secretion of Galectin-3 is thought to occur through an endoplasmic reticulum/Golgi complex-independent pathway that remains unclear. The studies on regulation of Galectin-3 secretion by Sato and Hughes (28) demonstrated that the secretion of Galectin-3 by murine peritoneal macrophages was strongly stimulated by treatment with calcium ionophores, suggesting that Ca 2ϩ influx into the cell might play a role in the mechanism of Galectin-3 secretion. Sano et al. (29) have shown that Galectin-3 acts as a chemotactic factor for human monocytes in a much more potent fashion than even MCP-1. Stimulation of monocytes with Galectin-3 induces a Ca 2ϩ influx. Monocytes migrate in response to Galectin-3 in a dose-dependent manner. Both monocyte migration and the intracellular Ca 2ϩ signal can be completely blocked with pertussis toxin, which implies the involvement of G protein-coupled pathway.
Macrophages, the major phagocytes of the human immune system, play a very important role in the internalization and later degradation of pathogens. Galectin-3 has been shown to play a critical role in macrophage phagocytosis of both IgG-opsonized erythrocytes and apoptotic cells using Galectin-3-deficient cells from Galectin-3 knockout mice (30) .
We believe that the interaction between Galectin-3 and the xenoantigen Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R involves a complicated pathway beginning with the initial recognition of the xenoantigen, subsequent activation of monocyte, and possibly secretion of additional Galectin-3 into the extracellular environment, resulting in the chemotactic attraction of more monocytes into the xenograft. Further studies on the regulation of Galectin-3 secretion should be pursued to further elucidate the exact mechanism by which the Galectin-3 and Gal-␣(1,3)Gal-␤(1,4)GlcNAc-R interaction facilitates DXR.
With the emergence of ␣-galactosyltransferase (␣(1,3)GT) knockout pigs, the role of Galectin-3 will remain speculative pending additional studies on endothelial cells from these animals. However, it may still be important in the facilitation of DXR. Unlike anti-Gal Abs that bind specifically to the terminal ␣(1, 3)galactose linkage (31), Galectin-3 binds primarily to the core N-acetyllactosamine (LacNAc) structure (Fig. 9) (32) . The terminal galactose molecule greatly increases the binding affinity of galectin-3 (16), possibly through availability of more binding sites in the carbohydrate recognition domain (33) , or binding contributions through folding of the flexible N-terminal domain (34) . Therefore, removal of the ␣(1,3)GT gene may decrease the binding affinity for Galectin-3, but will not eliminate the binding site itself.
As opposed to the increasing effect of ␣-gal, other nonreducing saccharides terminal to LacNAc can reduce the binding ability of Galectin-3 (16). Holikova et al. (35) have shown that removal of ␣(2, 6) and ␣(2, 3)sialic acid increases Galectin-3 binding. Porcine and humans differ in the structure of their sialic acid residues. Although humans use N-acetylneuraminic acid, which lacks a carbon 5 hydroxyl group, all other animals (except chickens) retain N-glycolylneuraminic acid. This fact could also contribute to the differential binding of Galectin-3 to pig vs human cells even in ␣(1,3)GT knockout animals. As well, ␣(1,3)GT knockout pigs may not eliminate DXR because removal of the GT enzyme could leave many of the LacNAc structures uncapped, as seen in ␣(1,3)GT knockout mice (36) . In addition to eliminating the ␣ (1,3) GT enzyme, it may be necessary to substitute other glycosyltransferase genes that could cap the LacNAc and decrease galectin-3 binding. According to Patnaik et al. (37) , certain fucosyltransferases and sialyltransferases decrease Galectin-3 binding. Kwiatkowski et al. (38) showed that monocyte adhesion to PAEC was decreased when PAEC were transfected with the ␣-fucosyltransferase, a competitive enzyme to ␣ (1,3) GT. Therefore, subtle differences in cell surface glycosylation could contribute to the amount of Galectin-3 bound to the cell. Future studies will be needed to address the role of Galectin-3 in ␣(1,3)GT knockout animals.
In summary, our current study has demonstrated that human Galectin-3 is a receptor recognizing the major xenoantigen, which leads to monocyte accumulation, one of the major mechanisms leading to DXR. Galectin-3 could provide another pharmacological target by which DXR may be inhibited. FIGURE 9. Anti-Gal Ab and Galectin-3 bind to different sites on ␣-gal. Galectin-3 primarily binds to the C4 and C6 hydroxyl groups of the galactose molecule next to GlcNAc and the C3 hydroxyl group on the GlcNAc molecule. Other bonds can be made to the N-acetyl group of GlcNAc, as well as to the terminal galactose molecule. Conversely, the anti-gal Ab binds mainly to the 2C and 4C hydroxyl groups of the nonreducing terminal galactose molecule.
